Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01003028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reduction of Remifentanil-related Complications

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 1, 2023 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv9
  2. Primary completion date: Dec 2015 to Dec 1, 2025 Start date: Nov 2015 to Nov 1, 2024 · Completion date: Dec 2015 to Dec 1, 2026 · Site details revised · 1 morev8 Show 4 more changesShow less
    • Start date: Nov 2015 to Nov 1, 2024
    • Completion date: Dec 2015 to Dec 1, 2026
    • Site details revised
    • Study title shortened, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv7
  4. Primary and study completion dates: Dec 2013 to Dec 2015 Start date: Nov 2012 to Nov 2015v6 Show 1 more changeShow less
    • Start date: Nov 2012 to Nov 2015
  5. Primary and study completion dates: Dec 2012 to Dec 2013 Start date: Nov 2011 to Nov 2012v5 Show 1 more changeShow less
    • Start date: Nov 2011 to Nov 2012
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Dec 2010 to Dec 2012 Start date: Nov 2009 to Nov 2011 · Trial status: Active, Not Recruiting to Not Yet Recruiting · Completion date: Jan 2011 to Dec 2012 · 1 morev4 Show 4 more changesShow less
    • Start date: Nov 2009 to Nov 2011
    • Trial status: Active, Not Recruiting to Not Yet Recruiting
    • Completion date: Jan 2011 to Dec 2012
    • Site contact updated
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Active, Not Recruiting Site contact updatedv2 Show 1 more changeShow less
    • Site contact updated
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.
Trial Details
NCT Number NCT01003028
Lead Sponsor Seoul National University Hospital
Conditions Anesthesia
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov